Journal of Clinical Respiratory Medicine

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Journal of Clinical Respiratory Medicine 44 7897 074717

Case Report - Journal of Clinical Respiratory Medicine (2025) Volume 9, Issue 1

Emerging Biomarkers in the Early Diagnosis and Prognosis of Chronic Obstructive Pulmonary Disease (COPD)

Thierry Troosters *

Department of Rehabilitation Sciences, KU Leuven, Belgium

*Corresponding Author:
Thierry Troosters
Department of Rehabilitation Sciences, KU Leuven, Belgium
E-mail: thierry.troosters@kuleuven.be

Received: 1-Mar-2025, Manuscript No. aajcrm-25-167785; Editor assigned: 4-Mar-2025, PreQC No. aajcrm-25-167785 (PQ) Reviewed:17-Mar-2025, QC No. aajcrm-25-167785Revised:24-Mar-2025, Manuscript No. aajcrm-25-167785; Published:31-Mar-2025, DOI: 10.35841/ aajcrm - 9.1.253

Citation: Troosters T. Emerging biomarkers in the early diagnosis and prognosis of chronic obstructive pulmonary disease (COPD). J Clin Resp Med. 2025;9(1):253

Visit for more related articles at Journal of Clinical Respiratory Medicine

Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory disorder characterized by persistent airflow limitation and chronic inflammation. Despite being a leading cause of morbidity and mortality worldwide, COPD is often underdiagnosed until it reaches an advanced stage. Traditional diagnostic tools such as spirometry are essential but limited in their ability to predict disease progression or tailor personalized treatment. Recent advancements in molecular biology and clinical research have led to the identification of emerging biomarkers that offer promise for early diagnosis, improved prognostication, and targeted therapeutic strategies [1].

Among the most widely studied biomarkers are blood eosinophils and immunoglobulin E (IgE). Elevated eosinophil counts are associated with increased exacerbation risk and responsiveness to corticosteroid therapy, making them valuable in guiding treatment decisions. Similarly, elevated IgE levels, particularly among current smokers and males, have been linked to a higher frequency of exacerbations and more rapid lung function decline. These biomarkers not only facilitate earlier diagnosis but also help in stratifying patients based on inflammatory profiles, enabling more precise and individualized management plans [2].

Inflammatory markers such as C-reactive protein (CRP), fibrinogen, interleukins (e.g., IL-6, IL-8, IL-33), and tumor necrosis factor-alpha (TNF-α) are also gaining traction in COPD research. Elevated CRP and fibrinogen levels have been correlated with increased systemic inflammation, frequent exacerbations, and higher mortality. These markers may be useful not only in identifying high-risk individuals but also in monitoring disease progression and therapeutic response. The inclusion of such systemic biomarkers in clinical practice may offer a more comprehensive understanding of COPD's heterogeneous nature [3].

In addition to blood-based biomarkers, novel proteins such as surfactant protein D (SP-D), club cell secretory protein (CC16), and soluble receptor for advanced glycation end-products (sRAGE) have shown potential in assessing lung tissue damage, disease severity, and long-term outcomes [4].

These emerging markers are particularly useful in identifying subclinical changes in the lungs before significant functional decline is evident on spirometry. Furthermore, non-invasive techniques such as measuring fractional exhaled nitric oxide (FeNO) are being explored for detecting airway inflammation, especially in patients with overlapping asthma-COPD features [5].

Conclusion

The identification and validation of emerging biomarkers represent a pivotal shift in the clinical approach to COPD, offering new avenues for early diagnosis, personalized prognosis, and targeted treatment strategies. As research continues to evolve, integrating biomarker profiling into routine clinical practice may transform COPD management by enabling proactive intervention, reducing disease burden, and improving patient outcomes. However, further longitudinal studies and clinical validations are essential to establish the utility and standardization of these biomarkers across diverse populations.

References

  1. Shaw JG, Vaughan A, Dent AG, et al. Biomarkers of progression of chronic obstructive pulmonary disease (COPD). J Thorac Dis. 2014;6(11):1532.

    2. Indexed at, Google Scholar, Cross Ref

  2. Li CL, Liu SF. Exploring molecular mechanisms and biomarkers in COPD: An overview of current advancements and perspectives. Int J Mol Sci. 2024;25(13):7347.

    3. Indexed at, Google Scholar, Cross Ref

  3. Dahl M, Nordestgaard BG. Markers of early disease and prognosis in COPD. Int J Chron Obstruct Pulmon Dis. 2009:157-67.

    4. Indexed at, Google Scholar, Cross Ref

  4. Rosenberg SR, Kalhan R. Biomarkers in chronic obstructive pulmonary disease. Transl Res. 2012;159(4):228-37.

    5. Indexed at, Google Scholar, Cross Ref

  5. Barnes PJ, Chowdhury B, Kharitonov SA, et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174(1):6-14.

    6. Indexed at, Google Scholar, Cross Ref

Get the App